Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

The Lancet

Volumn 390, Issue 10108, 2017, Pages 2143-2159

  Huh, Warner K ^a   Joura, Elmar A ^b   Giuliano, Anna R ^c   Iversen, Ole Erik ^d,e   de Andrade, Rosires Pereira ^f   Ault, Kevin A ^g   Bartholomew, Deborah ^h   Cestero, Ramon M ⁱ   Fedrizzi, Edison N ^j   Hirschberg, Angelica L ^k,l   Mayrand, Marie Hélène ^m,n   Ruiz Sternberg, Angela Maria ^o   Stapleton, Jack T ^p,q   Wiley, Dorothy J ^r   Ferenczy, Alex ^s   Kurman, Robert ^t   Ronnett, Brigitte M ^u   Stoler, Mark H ^v   Cuzick, Jack ^w   Garland, Suzanne M ^x   Kjaer, Susanne K ^y   Bautista, Oliver M ^z   Haupt, Richard ^z   Moeller, Erin ^z   Ritter, Michael ^z   Roberts, Christine C ^z   Shields, Christine ^z   Luxembourg, Alain ^z   more..

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^g UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^h THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l Department of Women's and Children's Health ^*  (Sweden)

^m UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁿ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^o UNIVERSIDAD DEL ROSARIO   (Colombia)

^p UNIVERSITY OF IOWA   (United States)

^q VETERANS AFFAIRS MEDICAL CENTER   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s MCGILL UNIVERSITY   (Canada)

^t JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^u DEPARTMENT OF PATHOLOGY   (United States)

^v UNIVERSITY OF VIRGINIA   (United States)

^w QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^x UNIVERSITY OF MELBOURNE   (Australia)

^y UNIVERSITY OF COPENHAGEN   (Denmark)

^z MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE; VIRUS ANTIBODY;

ADENOCARCINOMA IN SITU; ADOLESCENT; ADULT; ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; APPENDICITIS; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FETUS WASTAGE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IMMUNOASSAY; INCIDENCE; INFECTION PREVENTION; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; OUTCOME ASSESSMENT; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SPONTANEOUS ABORTION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VACCINE IMMUNOGENICITY; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVA CANCER; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PATIENT SAFETY; PRIMARY PREVENTION; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 6; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNOASSAY; IMMUNOGENICITY, VACCINE; INJECTIONS, INTRAMUSCULAR; PAPILLOMAVIRUS INFECTIONS; PATIENT COMPLIANCE; PATIENT SAFETY; PRIMARY PREVENTION; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 85028880750     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31821-4     Document Type: Article

References (30)

1. Forman, D, de Martel, C, Lacey, CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 30:suppl 5 (2012), F12–F23.
2. Schiller, JT, Castellsagué, X, Garland, SM, A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:suppl 5 (2012), F123–F138.
3. de Sanjose, S, Quint, WG, Alemany, L, et al., on behalf of the Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11 (2010), 1048–1056.
4. Garland, SM, Hernandez-Avila, M, Wheeler, CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007), 1928–1943.
5. Drolet, M, Bénard, É, Boily, MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15 (2015), 565–580.
6. Malagón, T, Drolet, M, Boily, M-C, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 781–789.
7. Joura, EA, Ault, A, Bosch, FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 23 (2014), 1997–2008.
8. Serrano, B, de Sanjosé, S, Tous, S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer 51 (2015), 1732–1741.
9. Alemany, L, Saunier, M, Alvarado-Cabrero, I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 136 (2015), 98–107.
10. Garland, SM, Steben, M, Sings, HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 199 (2009), 805–814.
11. Luxembourg, A, Bautista, O, Moeller, E, Ritter, M, Chen, J, Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp Clin Trials 42 (2015), 18–25.
12. Joura, EA, Giuliano, AR, Iversen, OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372 (2015), 711–723.
13. Chen, YH, Gesser, R, Luxembourg, A, A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials 12 (2015), 84–90.
14. Luxembourg, A, Brown, D, Bouchard, C, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother 11 (2015), 1313–1322.
15. Else, EA, Swoyer, R, Zhang, Y, et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol 49 (2011), 1907–1912.
16. Roberts, CC, Swoyer, R, Bryan, JT, Taddeo, FJ, Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection. J Clin Microbiol 49 (2011), 1899–1906.
17. Roberts, C, Green, T, Hess, E, et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother 10 (2014), 2168–2174.
18. Brown, D, Müller, M, Sehr, P, et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. Vaccine 32 (2014), 5880–5887.
19. Moreira, ED, Block, SL, Ferris, D, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 Phase III clinical trials. Pediatrics, 138, 2016, e20154387.
20. Chan, ISF, Bohidar, NR, Exact power and sample size for vaccine efficacy studies. Comm Stat Theory Methods 27 (1998), 1305–1322.
21. Guan, P, Howell-Jones, R, Li, N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131 (2012), 2349–2359.
22. Safaeian, M, Schiffman, M, Gage, J, Solomon, D, Wheeler, CM, Castle, PE, Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res 69 (2009), 3262–3266.
23. Serrano, B, Alemany, L, Tous, S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer, 7, 2012, 38.
24. Ault, KA, Joura, EA, Kjaer, SK, et al. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer 128 (2011), 1344–1353.
25. Barr, E, Gause, CK, Bautista, OM, et al. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol, 198, 2008, 261.
26. Kjaer, SK, Sigurdsson, K, Iversen, OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2 (2009), 868–878.
27. Majewski, S, Bosch, FX, Dillner, J, et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol 23 (2009), 1147–1155.
28. Perez, G, Lazcano-Ponce, E, Hernandez-Avila, M, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 122 (2008), 1311–1318.
29. Tay, EH, Garland, S, Tang, G, et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. Int J Gynaecol Obstet 102 (2008), 275–283.
30. Kjaer, SK, Nygård, M, Dillner, J, et al. Long-term effectiveness and safety of Gardasil™ in the Nordic countries. http://www.eurogin.com/2015/images/pdf/eurogin-2015_abstracts_part_2.pdf, 2015 (accessed Aug 8, 2016).